Communiqués B.R.A.I.N. Biotechnology Research and Information Network AG OTC Markets

Actions

BRNB.F

DE0005203947

Services et équipements environnementaux

Communiqués

28/05	BRAIN Biotech : Management Statement 6M 2025/26 (BRAIN 6M 2025 26 Managementstatement)	PU
28/05	BRAIN Biotech : Half-year report as of 31 March 2026 (6M)	PU
28/05	BRAIN Biotech AG reports half-year figures for fiscal year 2025/26 and confirms full year guidance	EQ
23/03	BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology	EQ
11/03	Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG	EQ
09/03	BRAIN Biotech : Sustainability Report VSME for FJ 2023/24	PU
25/02	BRAIN Biotech : Management Statement 3M 2025/26 (BRAIN Managementstatement 3M 2025 26 )	PU
25/02	BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase® Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds	PU
25/02	BRAIN Biotech : Quarterly Statement as of 31 December 2025 (3M)	PU
25/02	BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds	EQ
14/01	BRAIN Biotech : Management Statement 12M 2024/25 (BRAIN Managementstatement 12M 2024 25)	PU
14/01	BRAIN Biotech : ESG Data Sheet 2023/24	PU
14/01	FY 2024/25: BRAIN Biotech AG benefits from successful monetization of projects and strong corporate cost control	EQ
09/09/25	BRAIN Biotech : Johan Jansén-Storbacka takes over as head of BRAINBiocatalysts' enzyme product business	PU
03/09/25	BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business	EQ
28/08/25	BRAIN Biotech : Management Statement 9M 2024/25 (BRAIN Management Statement 9M24 25)	PU
28/08/25	BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts	EQ
28/08/25	BRAIN Biotech : Quarterly Statement as of 30 June 2025 (9M)	PU
25/08/25	Corbion and BRAIN Biotech team to shape the future of innovation in nature-based ingredient technologies	EQ
23/07/25	Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG	EQ
28/05/25	BRAIN Biotech : Management Statement 6M 2024/25 (BRAIN IR Management 6M 2024 25)	PU
28/05/25	BRAIN Biotech : Half-year report as of 31 March 2025 (6M)	PU
28/05/25	BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25	EQ
20/05/25	BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center	EQ
12/05/25	BRAIN Biotech : IR Presentation May 2025 (20250512 IR BRAIN May2025)	PU